Millennium Management’s Aligos Therapeutics ALGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-12,315
Closed -$88.8K 5989
2025
Q2
$88.8K Buy
+12,315
New +$73.7K ﹤0.01% 5526
2024
Q3
Sell
-1,195
Closed -$10.5K 6053
2024
Q2
$10.5K Sell
1,195
-3,231
-73% -$56.8K ﹤0.01% 5605
2024
Q1
$108K Buy
4,426
+3,278
+286% +$65.3K ﹤0.01% 5555
2023
Q4
$19.1K Sell
1,148
-2,524
-69% -$43.4K ﹤0.01% 5641
2023
Q3
$68.6K Sell
3,672
-3,363
-48% -$74.5K ﹤0.01% 5421
2023
Q2
$171K Sell
7,035
-9,100
-56% -$244K ﹤0.01% 5179
2023
Q1
$353K Buy
16,135
+1,282
+9% +$49K ﹤0.01% 4807
2022
Q4
$354K Buy
14,853
+1,568
+12% +$39.5K ﹤0.01% 4975
2022
Q3
$365K Sell
13,285
-5,291
-28% -$176K ﹤0.01% 5217
2022
Q2
$562K Buy
+18,576
New +$631K ﹤0.01% 4858
2022
Q1
Sell
-925
Closed -$275K 6849
2021
Q4
$275K Sell
925
-1,873
-67% -$683K ﹤0.01% 5630
2021
Q3
$1.08M Buy
+2,798
New +$1.11M ﹤0.01% 4582
2021
Q2
Sell
-1,303
Closed -$741K 6471
2021
Q1
$741K Buy
+1,303
New +$867K ﹤0.01% 4485

Other funds holding ALGS

Millennium Management's ALGS Position: Q3 2025 in Review

Millennium Management sold out of Aligos Therapeutics (ALGS) in Q3 2025, closing a stake of 12,315 shares — an estimated $88.8K sold.

Millennium Management first reported a position in ALGS in Q1 2021 and held it in 13 quarters. The position peaked at $1.08M in Q3 2021. 33 funds tracked by Wall St. Rank hold ALGS as of Q3 2025.

  • Millennium Management reported no remaining Aligos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Millennium Management sold 12,315 Aligos Therapeutics shares in Q3 2025, an estimated $88.8K.
  • Millennium Management first reported a position in Aligos Therapeutics in Q1 2021 and held it in 13 quarters.
  • Millennium Management's Aligos Therapeutics position peaked at $1.08M in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.